RBC Capital analyst Brian Abrahams maintained a Hold rating on Galapagos on February 19 and set a price target of $87.00. The company’s shares closed last Friday at $86.28, close to its 52-week low of $81.89.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 10.8% and a 51.1% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.
Galapagos has an analyst consensus of Hold, with a price target consensus of $105.15, which is a 26.6% upside from current levels. In a report issued on February 10, Maxim Group also downgraded the stock to Hold.
Homology Medicines (FIXX)
RBC Capital analyst Luca Issi maintained a Buy rating on Homology Medicines on February 18 and set a price target of $30.00. The company’s shares closed last Friday at $12.05.
According to TipRanks.com, Issi is a 2-star analyst with an average return of 5.0% and a 44.4% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crispr Therapeutics AG, and Ionis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Homology Medicines with a $29.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.